All In Biotech

Drug Trial Radar · NCT03399786

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

65

Actual

Start

Jan 18, 2018

Primary completion

Jun 10, 2019

Study completion Mar 17, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial hypercholesterolemia (HoFH). The secondary objectives of the study are to evaluate the effect of evinacumab IV on other lipid parameters, evaluate the effect of evinacumab on LDL-C goal attainment, assess the effect of evinacumab on eligibility for apheresis (using German and US apheresis criteria), evaluate the safety and tolerability of evinacumab in patients with HoFH, assess the pharmacokinetics (PK) of evinacumab in patients with HoFH and evaluate the potential development of anti-evinacumab antibodies.

Conditions

  • Homozygous Familial Hypercholesterolemia

Interventions

  • evinacumabDrug

    IV administration of evinacumab

  • PlaceboDrug

    IV administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand)Time frame: Week 24

Locations

30 sites in 11 countries. Site status is shown where the registry gives one.

  • Regeneron Research Site

    Boca Raton, Florida

  • Regeneron Research Site

    Boston, Massachusetts

  • Regeneron Research Site

    New York, New York

  • Regeneron Research Site

    Cincinnati, Ohio

  • Regeneron Research Site

    Portland, Oregon

  • Regeneron Research Site

    Dallas, Texas

  • Regeneron Research Site

    Camperdown, New South Wales, Australia

  • Regeneron Research Site

    Perth, Western Australia, Australia

  • Regeneron Research Site

    Innsbruck, Austria

  • Regeneron Research Site

    Chicoutimi, Quebec, Canada

  • Regeneron Research Site

    Québec, Quebec, Canada

  • Regeneron Research Site

    Marseille, France

  • Regeneron Research Site

    Paris, Cedex, France

  • Regeneron Research Site

    Athens, Greece

  • Regeneron Research Site

    Ioannina, Ioannina, Greece

  • Regeneron Research Site # 2

    Naples, Italy

  • Regeneron Research Site

    Osaka, Japan

  • Regeneron Research Site

    Kurume, Fukuoka, Japan

  • Regeneron Research Site

    Nishinomiya, Hyōgo, Japan

  • Regeneron Research Site

    Kanazawa, Ishikawa-ken, Japan

  • Regeneron Research Site #3

    Suita, Osaka, Japan

  • Regeneron Research Site

    Suita, Osaka, Japan

  • Regeneron Research Site

    Amsterdam, Netherlands

  • Regeneron Research Site

    Rotterdam, Netherlands

  • Regeneron Research Site

    Parktown, Johannesburg, South Africa

  • Regeneron Research Site

    Ivano-Frankivsk, Ukraine

  • Regeneron Research Site

    Kharkiv, Ukraine

  • Regeneron Research Site #2

    Kharkiv, Ukraine

  • Regeneron Research Site #2

    Kyiv, Ukraine

  • Regeneron Research Site

    Kyiv, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.